TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03955445: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Sponsor: Novartis Pharmaceuticals · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 225 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT03955445 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03955445 Rescue Dossier →